BCL2L1 and lung carcinoma: Down-regulated expression of lncRNA MEG3 is involved in cisplatinum resistance through p53 and Bcl-xl controlled gene expression in lung carcinoma cells [45], although additional epigenetic evidences must be obtained in lung cancer patients.